Document Type : Review article
Authors
Abstract
IUGR is a major causes and silent illness and death in the embryonic and infants population, which in it infants growth potential is less than natural state. IUGR phrase and small for gestation age often used interchangeably; Although there is small difference between these two. IUGR/SGA as a result different etiology including maternal factors, placenta and fetus arise. That recently genetic factors added to it. IUGR may be caused by maternal smoking, infections agents and chromosomal or genetic abnormalities, maternal abnormalities, but in most cases secondary cause is placenta insufficiency. IUGR often causes complications in the third trimester of pregnancy which is associated with symptoms of preeclampsia. the Pathophysiology of IUGR is associated with placenta insufficiency it remains unclear, but the damage is usually caused due to failure of trophoblast invasion which causes intermittent blood flow the space between the intervillous that this also in turn causes local oxidative stress.
Keywords
Main Subjects
[1]. Toutain J, Prochazkova-Carlotti M, Cappellen D, Jarne A, Chevret E, Ferrer J, et al. Reduced placental telomere length during pregnancies complicated by intrauterine growth restriction. PloS one. 2013; 8(1): e54013.
[2]. Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR): epidemiology and etiology. Pediatric endocrinology reviews: PER. 2009; 6: 332-6.
[3]. Rab A, Szentpéteri I, Kornya L, Börzsönyi B, Demendi C, Joó JG. Placental gene expression patterns of epidermal growth factor in intrauterine growth restriction. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013; 170(1): 96-9.
[4]. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among premature neonates. American journalof obstetrics and gynecology. 2004; 191(2): 481-7.
[5]. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ (Clinical research ed). 2016; 353:i1753.
[6]. Grivell R, Dodd J, Robinson J. The prevention and treatment of intrauterine growth restriction. Best practice & research Clinical obstetrics & gynaecology. 2009; 23(6): 795-807.
[7]. Gaccioli F, Lager S. Placental Nutrient Transport and Intrauterine Growth Restriction. Frontiers in physiology. 2016; 7.
[8]. Lawn JE, Cousens S, Zupan J, Team LNSS. 4 million neonatal deaths: when? Where? Why? The lancet. 2005; 365(9462): 891-900.
[9]. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. American journal of obstetrics and gynecology. 1995; 173(4): 1049-57.
[10]. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? American journal of obstetrics and gynecology. 2006; 194(4): 921-31.
[11]. Czeizel AE. Intrauterine growth retardation asa potential endpoint in mutation epidemiology. Mutation Research/Reviews in Genetic Toxicology. 1993; 296(3): 211-9.
[12]. Hăşmăşanu MG, Bolboacă SD, Drugan TC, Matyas M, Zaharie GC. Parental factors associated with intrauterine growth restriction. Srpski arhiv za celokupno lekarstvo. 2015; 143(11-12): 701-6.
[13]. Muresan D, Rotar IC, Stamatian F. The usefulness of fetal Doppler evaluation in early versus late onset intrauterine growth restriction. Review of the literature. Medical ultrasonography. 2016; 18(1): 19-30.
[14]. Demirci O, Selçuk S, Kumru P, Asoğlu MR, Mahmutoğlu D, Boza B, et al. Maternal and fetal risk factors affecting perinatal mortality in early and late fetal growth restriction. Taiwanese Journal of Obstetrics and Gynecology. 2015; 54(6): 700-4.
[15]. Wadhwa PD, Buss C, Entringer S, Swanson JM, editors. Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Seminars in reproductive medicine; 2009: NIH Public Access.
[16]. Gonzalez-RodriguezP, Cantu J, O'Neil D, Seferovic M, Goodspeed DM, Suter MA, et al. Alterations in Expression of Imprinted Genes from the H19/IGF2 Loci in a Multigenerational Model of IUGR. American journal of obstetrics and gynecology. 2016.
[17]. McMinn J, Wei M, Schupf N, Cusmai J, Johnson E, Smith A, et al. Unbalanced placental expression of imprinted genes in human intrauterine growth restriction. Placenta. 2006;27(6):540-9.
[18]. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. Canadian Medical Association Journal. 2008; 178(6): 701-11.
[19]. Resnik R. Intrauterine growth restriction. Obstetrics & Gynecology. 2002; 99(3): 490-6.
[20]. Darmochwal-Kolarz D, Kolarz B, Korzeniewski M, Kimber-Trojnar Z, Patro-Malysza J, Mierzynski R, et al. A prevention of pre-eclampsia with the use of acetylsalicylic acid and low-molecular weight heparin-molecular mechanisms. Current pharmaceutical biotechnology. 2016.
[21]. Gutaj P, Wender-Ozegowska E. Diagnosis and Management of IUGR in Pregnancy Complicated by Type 1 Diabetes Mellitus. Current diabetes reports. 2016;16(5):39.
[22]. Beischer NA. Treatment of fetal growth retardation. Australian and New Zealand Journal of Obstetrics and Gynaecology. 1978; 18(1): 28-33.
)